Literature DB >> 26599796

Saline Flush After Rocuronium Bolus Reduces Onset Time and Prolongs Duration of Effect: A Randomized Clinical Trial.

Sayaka Ishigaki1, Kenichi Masui, Tomiei Kazama.   

Abstract

BACKGROUND: Circulatory factors modify the onset time of neuromuscular-blocking drugs. Therefore, we hypothesized that infusion of a saline flush immediately after rocuronium administration would shorten the onset time without influencing the duration of the rocuronium effect.
METHODS: Forty-eight patients were randomly allocated to the control or saline flush group. Anesthesia was induced and maintained with propofol and remifentanil, and all patients received 0.6 mg/kg rocuronium in 10 mL of normal saline. In the saline flush group, 20 mL normal saline was immediately infused after rocuronium administration. Neuromuscular blockade was assessed using acceleromyography at the adductor pollicis muscle with train-of-four (TOF) stimulation. The neuromuscular indices for rocuronium were calculated as follows: the latent onset time, defined as the time from the start of rocuronium infusion until first occurrence of depression of the first twitch of the TOF (T1) ≥5%; onset time, defined as the time from the start of rocuronium infusion until first occurrence of depression of the T1 ≥95%; clinical duration, defined as the time from the start of rocuronium administration until T1 recovered to 25% of the final T1 value; recovery index, defined as the time for recovery of T1 from 25% to 75% of the final T1 value; and the total recovery time, defined as the time from the start of rocuronium administration until reaching a TOF ratio of 0.9. Significance was designated at P <0.05.
RESULTS: The measured latent onset time and onset time were significantly shorter in the saline flush group than the control group by 15 seconds (95.2% confidence interval, 0-15, P = 0.007) and 15 seconds (0-30, P = 0.018), respectively. Saline flush significantly depressed the T1 height at 30, 45, and 60 seconds after the rocuronium bolus by 17%, 24%, and 14%, respectively. In addition, the recovery phase was significantly prolonged in the saline flush group. The mean clinical duration (5th-95th percentile range) in the saline flush group and control group was 35 minutes (27-63 minutes) and 31 minutes (19-48 minutes; P = 0.032), respectively; the recovery index was 13 minutes (8-25 minutes) and 10 minutes (7-19 minutes; P = 0.019), respectively; and the total recovery time was 61 minutes (44-108 minutes) and 50 minutes (35-93 minutes; P = 0.048), respectively.
CONCLUSIONS: Administering a 20-mL saline flush immediately after infusion of 0.6 mg/kg rocuronium in 10 mL normal saline shortened the onset time and prolonged the recovery phase of neuromuscular blockade.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26599796     DOI: 10.1213/ANE.0000000000001094

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

1.  Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models.

Authors:  Kenichi Masui; Sayaka Ishigaki; Atsuko Tomita; Hiroshi Otake
Journal:  J Anesth       Date:  2018-08-11       Impact factor: 2.078

2.  The Role of Bolus Injection of Saline with Arm Elevation on Rocuronium onset Time: A Randomized Control Study.

Authors:  Malavika Kulkarni; L S Chuchendra; P J Bhavya
Journal:  Anesth Essays Res       Date:  2018 Jan-Mar

3.  The prediction of intraoperative cervical cord function changes by different motor evoked potentials phenotypes in cervical myelopathy patients.

Authors:  Shujie Wang; Zhifu Ren; Jia Liu; Jianguo Zhang; Ye Tian
Journal:  BMC Neurol       Date:  2020-05-30       Impact factor: 2.474

4.  A Comparison of Oxygenation Efficacy between High-Flow Nasal Cannulas and Standard Facemasks during Elective Tracheal Intubation for Patients with Obesity: A Randomized Controlled Trial.

Authors:  Yu-Ming Wu; Chun-Cheng Li; Shih-Yu Huang; Yen-Hao Su; Chien-Wun Wang; Jui-Tai Chen; Shih-Chiang Shen; Po-Han Lo; Yun-Ling Yang; Yih-Giun Cherng; Hsiang-Ling Wu; Ying-Hsuan Tai
Journal:  J Clin Med       Date:  2022-03-18       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.